Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

63
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

1
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
1
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

783
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
783
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

364
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
364
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

3
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
3

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cohort profile: Swiss personalized health network cohort consortium.

European journal of epidemiology·2026
Same author

Genome-wide association study of untargeted plasma metabolomic profiles identifies host genetic regulation in people with HIV.

HGG advances·2026
Same author

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trial.

Tobacco induced diseases·2026
Same author

Hepatitis B and C Prevention, Screening and Diagnostic Services at HIV Treatment Sites: International epidemiology Databases to Evaluate AIDS.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey.

PloS one·2026
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Hepatitis C: a changing epidemic.

Gilles Wandeler1, Jean-François Dufour2, Philip Bruggmann3

  • 1Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland, and Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Swiss Medical Weekly
|February 7, 2015
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) is a major global health issue, but new treatments offer hope for eradication. Challenges like poor testing rates, high drug costs, and reinfections must be overcome for public health success.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Related Experiment Videos

Last Updated: Apr 17, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Chronic hepatitis C virus (HCV) affects 3% of the global population, causing 500,000 deaths annually.
  • Persons who inject drugs (PWID) disproportionately bear the HCV burden in high-income nations.
  • Evolving HCV transmission patterns, including sexually transmitted infections among HIV-infected men who have sex with men, highlight the dynamic epidemic landscape.

Purpose of the Study:

  • To discuss the potential for HCV eradication as a public health target.
  • To examine the impact of revolutionary new interferon-free, oral antiviral treatments.
  • To identify key challenges hindering HCV elimination efforts.

Main Methods:

  • Review of current HCV epidemiology and treatment landscape.
  • Analysis of public health implications of new antiviral therapies.
  • Identification of barriers to HCV testing, treatment access, and sustained viral clearance.

Main Results:

  • New oral antiviral treatments demonstrate high efficacy in eradicating HCV infections.
  • HCV eradication is a feasible public health goal with current therapeutic advancements.
  • Significant challenges remain, including low HCV testing uptake, high treatment costs, and post-treatment reinfection risks.

Conclusions:

  • The advent of highly effective oral antivirals makes HCV eradication a realistic public health objective.
  • Addressing barriers such as insufficient testing, drug affordability, and reinfection prevention is critical for achieving global HCV elimination.
  • Continued research and public health initiatives are necessary to overcome remaining obstacles and achieve HCV eradication.